Turkish Journal of
GERIATRICS

Adnan Menderes üniversitesi Tıp Fakültesi İç Hastalıkları Anabilim Dalı, Hematoloji Bilim Dalı, AYDIN Thiazolidinediones (TZD), used to treat type 2 diabetes, are associated with an excess risk of heart failure (HF) and possibly acute myocardial infarction. However, the association between TZD use and cardiovascular events has not been adequately evaluated. A 74-year-old woman with longstanding type 2 diabetes mellitus treated with gliclazide began therapy with rosiglitazone 4 mg/day, which was increased to 8 mg/day after 1 month. She had no prior history of HF and had an excellent exercise tolerance. Over the first 4 weeks of rosiglitazone therapy, the patient experienced significant weight gain and subsequently developed HF. Rosiglitazone was discontinued and the edema resolved with diuretic (Furocemid 40mg/day) treatment. TZD should be considered as a cause in the differential diagnosis of HF and pulmonary edema in patients without a prior history of clinical HF or cardiac disease. Healthcare professionals should be aware of the possible association between TZD and HF. Keywords : Rosiglitazone, Heart failure